Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
Extravasation can present serious accidental complication of intravenous drug application. While monoclonal antibodies do not show the necrotic potential of cytotoxic chemotherapy drugs, considerable inflammatory toxicity can occur, necessitating standardized operating procedures for the management...
Main Authors: | Michael Launspach, Marita Seif, Theresa M. Thole, Patrick Jesse, Joachim Schulz, Johannes H. Schulte, Susan Bischoff, Angelika Eggert, Hedwig E. Deubzer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Children |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9067/8/2/91 |
Similar Items
-
Novel drug - dinutuximab for high-risk neuroblastoma
by: Supriya Kushwah, et al.
Published: (2018-01-01) -
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
by: Holger Lode, et al.
Published: (2020-05-01) -
Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
by: Neofit Spasov, et al.
Published: (2021-01-01) -
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
by: Annette Künkele, et al.
Published: (2021-07-01) -
Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
by: Jasminka Stepan Giljević, et al.
Published: (2022-06-01)